CATALYST BIOSCIENCES
Corporate Overview
12 January 2022
Forward looking statements
Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-looking statements. This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, our plans for CB 4332 and the rest of our complement programs, our plans to continue to support Biogen in the development of CB 2782-PEG, the statement that complement has broad potential, can be combined with conventional therapies and will open opportunities in multiple disease settings, as well as statements about the benefits of our protease engineering platform.
Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward- looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that Biogen could terminate our agreement for the development of CB 2782-PEG, that our complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that we may need to raise additional capital, and other risks described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. We do not assume any obligation to update any forward-looking statements, except as required by law.
© Catalyst Biosciences
2
Modulating Biological Systems with Nature's Regulatory Proteins
Proteases are nature's key regulatory proteins
Innovative engineered molecules to degrade or activate therapeutic targets
Applicable across multiple disease areas
We harness the regulatory power of proteases
© Catalyst Biosciences
Catalyst's protease platform in complement
Validated across three programs
CB 2782-PEG | CB 4332 PK extended CFI |
Best-in-class profile for dry AMD | Restoring balance to complement |
Extended pharmacodynamics | where CFI activity is insufficient |
Novel C3-degrader for | Engineered CFI entering |
dry AMD | the clinic in 2022 |
© Catalyst Biosciences
Engineered proteases
Protease platforms tailored to improve C3b & C4b regulation
C4b C3b
ProTUNE™
PLATFORM
C3b/C4b degrader platform delivering candidates in 2022
4
Unique targeted approach to complement regulation
Classical pathway
Lectin pathway
Alternative pathway
Cascade initiation | Cascade regulation | Terminal complement | ||
• C4b Degraders | • CB 2782-PEG | • C3a/C5a Degraders | ||
• C3b Degraders | • CB 4332 | |||
C3a Degrader | Inflammation | |||
Proinflammatory | ||||
Anaphylatoxins | ||||
C1r | C2 | C3a | ||
C4b | ||||
C1s | ||||
C4 | ||||
CB 4332 (CFI) | C3 | C5 | |||||
MASP | C4b Degrader | C3b | C5a | ||||
C3b Degrader | |||||||
Terminal Pathway | |||||||
CB 2782-PEG | C5a Degrader | Membrane attack complex | |||||
C3 | |||||||
FB FD | C3b | C5b | |||||
(H2O) |
© Catalyst Biosciences | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Catalyst Biosciences Inc. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 12:35:05 UTC.